Kornimate/medical-research-clean huggingface dataset:
telephone-based intervention in increasing adherence to adjuvant hormonal therapy in patients with breast cancer

Conditions: Stage IA Breast Cancer; Stage IB Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage 0 Breast Cancer

Summary: this pilot trial studies a telephone-based intervention to see if it increases adherence to adjuvant hormonal therapy in patients with breast cancer. increasing communication between doctors and patients with breast cancer may help patients to better follow recommendations on taking adjuvant hormonal treatment medication. a telephone-based intervention may help to increase doctor-patient communication and patients' adherence to their prescribed medication.

primary objectives: i. pilot test intervention effects on adherence to adjuvant hormonal therapy (aht) and explore trends in the adherence outcomes by demographic and psychosocial factors defined as acceptance, continuation, and adherence. secondary objectives: i. feasibility of study design defined as recruitment rate, rate of using intervention as instructed, rate of protocol completion, and completion of psycho-social questionnaires which have been associated with adherence to aht in the existing literature (i.e., depression, social support, pain, stress, fatigue, quality of life, pill taking attitude and behavior, perceived risk of breast cancer recurrence). tertiary objectives: i. surveying patients and physicians regarding their comments on the intervention components (i.e., video, text messaging, and app \[application\]) and overall study participation. outline: patients receive daily text messages reminding them to take aht and weekly interactive surveys delivered by a smart phone app for 3 months.

Eligibility criteria:
inclusion criteria: * eligible women are those who: * are post-menopausal, verified by: * post bilateral surgical oophorectomy; or * no spontaneous menses \>= 1 year; or * no menses for \< 1 year with follicle stimulating hormone (fsh) and estradiol levels in postmenopausal range, according to institutional standards * are diagnosed with primary breast cancer (bc) (stages i-iii) * eligible to receive aht (tamoxifen or an aromatase inhibitors \[ai\]) for the first time * completed all primary treatment * own a smartphone (in order to receive text messages and utilize the phone app) * agree to receive text messages on their smartphone over a 3-month period * provide consent and permission to review their medical records * plan to stay in the study area for 3 months
evaluation to assess safety and tolerability of dm199 in subjects with acute ischemic stroke

Conditions: Acute Ischemic Stroke

Summary: this is a phase ii study to assess the safety and tolerability of dm199 in acute ischemic stroke patients. the study will be randomized, placebo controlled at multiple centers.


Eligibility criteria:
inclusion criteria: 1. subject is \>/= 18 years of age 2. subject has been diagnosed with acute ischemic stroke with onset ≤ 24 hours from enrollment. 3. subject has nih stroke score (nihss) ≥ 6 and ≤ 25. 4. subject or legally authorized representative is willing and able to sign written informed consent. exclusion criteria: 1. subject is currently prescribed angiotensin-converting-enzyme inhibitors (acei) and is unable or unwilling to convert to another antihypertensive pharmacological treatment during the active treatment period (+5 days) of the study. 2. subject has a history of significant allergic diathesis such as urticaria, angioedema or anaphylaxis. 3. subjects with current malignancy or active malignancy ≤ 3 years prior to enrollment except basal cell or squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy and at least six months have elapsed since the procedure. 4. subject has a history of clinically significant acute bacterial, viral, or fungal systemic infections in the last four weeks prior to enrollment. 5. subject has clinical or laboratory evidence of an active infection at the time of enrollment. 6. subject has known alpha 1-antitrypsin deficiency (α1-antitrypsin deficiency). 7. subject has a known diagnosis of human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag), or anti-hepatitis c virus (anti-hcv) at screening. 8. subject is pregnant or nursing. 9. subject is male or female of childbearing potential, is participating in heterosexual sexual activity that could lead to pregnancy, and is unable or unwilling to practice medically effective contraception during the study. 10. subject is participating in any other investigational device or other drug study ≤ 4 weeks or 5 half-lives of the investigational product, whichever is longer. 11. subject does not have sufficient venous access for infusion of study treatment or blood sampling. 12. in the opinion of the investigator, subject is unlikely to be followed for the duration of t the study. 13. subject is unable or unwilling to comply with protocol requirements, including assessments, tests, and follow-up visits. 14. subject has any other medical condition which in the opinion of the investigator will make participation medically unsafe or interfere with the study results. 15. pre-stroke modified rankin scale ≥4
changes of low anterior resection syndrome and balance ability in patients with rectal cancer.

Conditions: Rectal Cancer

Summary: the purposes of this study are to explore the trajectory of symptom distress and balance ability in patients with rectal cancer.


Eligibility criteria:
inclusion criteria: 1. newly diagnosed rectal cancer 2. patients already know their condition. 3. aged 20 years and older. 4. consciously communicate in mandarin or taiwanese. 5. agreed with the interview and had signed the permit. exclusion criteria: 1. recurrent rectal cancer. 2. kps of patients less than 80
development and evaluation of a cognitive enhancement product made from selected thai herbs for menopausal women

Conditions: Healthy

Summary: this study is set up to determine the cognitive enhancing effect and consumption safety of the novel cognitive enhancement product made from the combined extract of z. mays (purple color) and p. amaryllifolius based-drink (mp1) in menopausal volunteer.

memory impairment is one of the common health problems in menopausal women. due to the therapeutic efficiency limitation, the searching for the protective intervention for this condition is required. based on the previous findings that the combined extract of z. mays (purple color) and p. amaryllifolius based-drink (mp1) could attenuate memory impairment in animal model of menopause, the investigators aimed to investigate the effect of mp1 functional drink on working memory, psychological fitness, possible underlying mechanism and the consumption safety in menopausal volunteers.

Eligibility criteria:
inclusion criteria: * healthy perimenopausal and postmenopausal women (\<5 years menstruation cessation) who live in northeastern of thailand. exclusion criteria: * subject who is diagnosed with one of the following: cardiovascular diseases, respiratory diseases,neuropsychological diseases, head injury, diabetes mellitus, liver disease, cancer, autoimmune disease and hematological disorder are excluded. * hysterectomy and/or oophorectomy * subject who use hormone or any drug exerts the influence on hypothalamic pituitary gonadal axis and nervous system. * body mass index \>27 * athlete or subject who has a regular exercise. * smoker or heavy drinker

Keywords: mp1 cognitive enhancing effect menopausal women
assessment of prevident sodium fluoride 1.1% toothpaste using an intra-oral remineralization-demineralization model

Conditions: Dental Caries

Summary: this is a double blind, cross-over, controlled clinical trial utilizing thirty (30) adults to evaluate remineralization of early caries lesions.


Eligibility criteria:
inclusion criteria: 1. male and/or female subjects 18 to 50 years inclusive 2. minimum of 20 natural uncrowned teeth (excluding third molars) must be present 3. willing to wear retainer 24 hours per day 4. no active, unrestored cavities 5. have normal salivary flow rate (stimulated and unstimulated flow of ≥0.7 ml/min and ≥ 0.2 ml/min respectively) ascertained from a preliminary sialometry 6. available throughout entire study 7. willing to use only assigned products for oral hygiene throughout the duration of the study 8. must give written informed consent 9. must be in good general health 10. no known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study exclusion criteria: 1. advanced periodontal disease 2. medical condition which requires premedication prior to dental visits/procedures 3. not enough teeth to secure the oral retainer 4. diseases of the soft or hard oral tissues 5. wear an orthodontic retainer(s) 6. impaired salivary function 7. current use drugs that can affect salivary flow 8. use antibiotics one (1) month prior to or during this study 9. positive urine test for pregnancy (a urine pregnancy test will be performed on female subjects of child-bearing potential) 10. participate in another clinical study one (1) week prior to the start of the washout period or during this 9-week study period 11. use tobacco products 12. allergic history to common toothpaste ingredients 13. immune compromised individuals (hiv, aids, immuno-suppressive drug therapy) as determined by review of medical history
clowns as treatment for preoperative anxiety in children: a randomized controlled trial

Conditions: Pre Operative Anxiety

Summary: this study wants to test the hypothesis that trained clowns can reduce anxiety in children undergoing general anesthesia. we will compare the effect of the clowns to the commonly used anti-anxiety medication we commonly use

the perioperative environment, often anxiety-provoking for adults, may be quite frightening for children. the detrimental effects of preoperative anxiety are not confined to the preoperative period. anxiety during induction of anesthesia is correlated with increased distress early in the postoperative period, (holms knud, kain) and maladaptive behavior will follow for the first 2 weeks following surgery in up to 54% of children. many preoperative systems allow parental, pharmacologic, and anticipatory interventions to facilitate a relaxed perioperative environment for children. unfortunately, scheduling conflicts, side effects, and limited resources conspire to limit their usefulness. for example, only 10% of respondents in a recent survey used parental presence during induction of anesthesia (ppia) for a majority of their patients. this may be due to the belief by some that parental anxiety may in fact increase children's anxiety. (bevans) according to the same survey, only 50% of children undergoing surgery receive sedating premedication. (kain). distraction techniques, such as the use of toys or video games, may also decrease perioperative anxiety, however their effectiveness during induction of anesthesia is not well characterized. the efficacy of toys and video games is somewhat dependent upon the child reaching certain developmental milestones. anesthesiologists continue to search for an easy and comprehensive method for anxiety reduction in the pediatric surgical population. we propose that specially trained professional clowns may allay preoperative anxiety and result in a smooth anesthetic induction.

Eligibility criteria:
inclusion criteria: * asa i and ii * children aged 2-8 years exclusion criteria: * previous surgery * asa \> ii * parents' refusal

Keywords: children anesthesia anxiety clowns
postural training device (upright) for back pain

Conditions: Back Pain Without Radiation; Back Pain, Low

Summary: participants with low back pain who are referred for physical therapy will be randomized to routine physical therapy or routine physical therapy plus receiving a postural training device

participants with low back pain who are referred for physical therapy will be randomized to routine physical therapy or routine physical therapy plus receiving a postural training device. physical therapy will be completed 1-2 times per week over 4-6 weeks. if randomized to the group that also receives a postural training device, one of the physical therapy sessions will instruct the patient on use of the device, which can be used thereafter as tolerated by the patient. at 6 weeks and 3 months, questionnaires that assess patients pain and function will be completed to assess outcomes

Eligibility criteria:
inclusion criteria: * age 18 - 65, capable of understanding and providing consent in english, capable of complying with the outcome instruments used, and capable of attending all planned therapy sessions * primary complaint of lumbar or thoracic pain thought to be at least in part due to mechanical/postural etiologies based on clinical presentation * 7 day average numeric pain rating score (nprs) of at least 4 on a 0-10 scale at baseline evaluation * pain duration of at least 2 months * patient owns and is familiar with the use of a personal smart phone * patient consents to treatment with postural based physical therapy. in order to maintain blinding, patients will not be provided with details of the treatment plan until after the randomization process has been performed. they will only be informed of the treatment protocol for the group to which they have been assigned. exclusion criteria: * \*history of prior thoracic or lumbar fusion surgery * acute spine fracture * current pregnancy * bmi over 40 * inability to sense upright vibration * active systemic inflammatory arthritis (e.g. rheumatoid arthritis, ankylosing spondylitis, lupus) * medical conditions causing significant functional disability (e.g. stroke, spinal cord injury, amputation) * severe chronic widespread pain or somatoform disorder (e.g. fibromyalgia) * severe clinical depression, or psychotic features * implanted electrical medical device (i.e. cardiac pacemaker/defibrillator, spinal cord stimulator, bladder stimulator) * allergic skin reaction to tapes or adhesives * worker's compensation claim or legal action related to the thoracic or lumbar pain * patients unable to read english and complete the assessment instruments * patients unable to attend assigned physical therapy sessions * incarcerated patients
an open-label, multicenter, phase 1b/2 study of the safety and efficacy of krt-232 combined with ruxolitinib in patients with primary myelofibrosis (pmf), post-polycythemia vera mf (post-pv-mf), or post-essential thrombocythemia mf (post et-mf) who have a suboptimal response to ruxolitinib

Conditions: Myelofibrosis

Summary: this is a phase 1b/2 study of krt-232 combined with ruxolitinib in subjects with mf who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. the primary objective of the study is to determine a recommended phase 2 dose (rp2d) of krt 232 in combination with ruxolitinib.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of pmf, post-pv mf, or post-et mf, as assessed by treating physician according to the world health organization (who) * treatment with ruxolitinib for ≥18 weeks prior to study entry, and on a stable dose of ruxolitinib in the 8 weeks prior to study entry * spleen ≥5 cm palpable below the llcm or ≥450 cm3 by mri or ct * patients must have at least 2 symptoms with a score of at least 1 on the mfsaf v4.0 * ecog performance status of 0 to 2 exclusion criteria: * patients who are positive for tp53 mutations * documented disease progression or clinical deterioration any time while on ruxolitinib treatment * patients who have had a documented spleen response to ruxolitinib. * prior splenectomy * prior mdm2 inhibitor therapy or p53-directed therapy

Keywords: navtemadlin
long-term outcomes after different management strategies for high-level cerebral arteriovenous malformation

Conditions: Arteriovenous Malformation of Brain

Summary: arteriovenous malformations (avms) are complex and rare cerebral vascular dysplasia. the main purpose of treatment is to avoid the neurological impairment caused by hemorrhagic stroke. the spetzler-martin (sm) grading system is widely used to estimate the risk of postoperative complication based on maximum avm nidus diameter, pattern of venous drainage, and eloquence of location. generally, grade i and ii are amenable to surgical resection alone. grade iii is typically treated via a multimodal approach, including microsurgical resection, embolization, and radiosurgery (srs). grade iv and v are generally observed unless ruptured. however, some previous studies indicated that despite the high rate of poor outcomes for high-level unruptured avms, the mortality for high-level unruptured avms are likely lower than untreated patients. with the development of new embolic materials and new intervention strategies, patients with high-level avms may have more opportunities to underwent more aggressive interventions. the ohavm study aims to clarify the clinical outcomes for patients with sm grade iv and v avms after different management strategies.

follow-up: in our neurosurgical center, follow-up was conducted for all patients at the first 3-6 months and annually after discharge by clinical visit and telephone interview. study overview: the population in the ohavm study will be divided into two parts. clinical and imaging data of high-level avm patients from 2012/04 to 2019/09 were retrospectively collected. and the high-level avm patients from 2019/09 to 2019/12 were prospectively collected. the intervention strategies in our institution for high-level avms are of four categories: microsurgical resection, embolization, embolization+radiosurgery, and single-stage hybrid surgery (embolization-resection). each participants will be followed at least for 5 year since enrollment. finally, we will clarify the clinical outcomes and prognostic predictors for patients with sm grade iv and v avms after different management strategies. sample size: about 1000 patients will be enrolled in this study, and half of them were unruptured. the population distribution of different management strategies is expected as follows: conservative:100 cases, microsurgical resection: 300 cases, embolization:250 cases, embolization+radiosurgery: 250 cases, single-stage hybrid surgery: 100 cases. study endpoints: the neurological function prognosis, occlusion rate and complications were evaluated at 2 weeks, 1 year, 3 years, 5 years after the treatment and the last follow-up, respectively.

Eligibility criteria:
inclusion criteria: 1. the diagnosis of avm was confirmed with digital subtraction angiography (dsa) and/or magnetic resonance imaging(mri). 2. the sm grade was iv and v. exclusion criteria: 1. patients with multiple avms. 2. patients with hereditary hemorrhagic telangiectasia (hht). 3. patients with missing clinical and imaging data.
an organ preservation strategies after chemoradiotherapy combined with immunotherapy for esophageal cancer (palace3).

Conditions: Esophageal Cancer

Summary: patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to receive neoadjuvant chemo-radiotherapy combined with immunotherapy post organ preservation strategy (experimental group) or neoadjuvant chemo-radiotherapy followed by surgery (control group). the 3-year overall survival rate is the primary outcome.

the investigators will conduct the open, multicenter, prospective, randomized controlled clinical study(palace3). patients with locally advanced esophageal squamous cell carcinoma will randomly assigned to either receive neoadjuvant synchronous radiotherapy and chemotherapy combined with immunotherapy followed by organ preservation strategy (experimental group, arm1) or neoadjuvant concurrent radiotherapy and chemotherapy followed by radical surgery (control group,arm 2). collect relevant data on preoperative treatment, re examination after neoadjuvant therapy, perioperative and long-term follow-up of patients, and evaluate the clinical treatment effects (ccr rate), surgical pathological results (pcr rate, r0 resection rate, tumor regression grade, lymph node positivity rate), neoadjuvant therapy and perioperative complications, long-term oncological effects (total survival, disease-free survival), and quality of life of the two treatment plans through statistical analysis.

Eligibility criteria:
inclusion criteria: * a patient will be eligible for inclusion in this study only if all of the following criteria apply: * histologically confirmed ct2-t4a,n0-n+,m0 resectable esophageal squamous cell carcinoma. * eastern cooperative oncology group (ecog) performance status 0-1 * patients approve and sign the informed consent exclusion criteria: * patients with active autoimmune disease or history of autoimmune disease. * patients who have a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications. * subjects with a history of symptomatic interstitial lung disease. * history of allergy to study drug components. * women must not be pregnant or breast-feeding. * men with female partners (wocbp) that are not willing to use contraception. * patient has received prior chemotherapy, radiotherapy, target therapy and immune therapy for this malignancy or for any other past malignancy. * medical conditions that, in the investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events

Keywords: chemoradiotherapy immunotherapy organ preservation active surveillance
exercise for brain health in the fight against alzheimer's disease

Conditions: Healthy Cognition

Summary: the investigators aim to compare the effects of a 6-month moderate intensity exercise training (et) intervention to a low intensity flexibility exercise control condition (fc) on brain function, cognition, and physical function in cognitively healthy and physically inactive older adults (ages 60-80). apolipoprotein e epsilon4 (apoe-ε4) allele carriers are known to be at substantially greater risk for cognitive decline and alzheimer's disease (ad). cognitively intact apoe-ε4 allele carriers, and non-carriers, will be randomly assigned to 6-months of either supervised moderate intensity aerobic exercise training (et) or supervised flexibility exercise control (fc). the et and fc each contain a group based exercise component and are run in local retirement communities near college park, md, or on the university of maryland college park campus. the primary aims of the study are to compare pre-intervention to post-intervention changes in episodic memory performance and mri biomarkers.


Eligibility criteria:
inclusion criteria: * 60 to 80 years old * fluent in english * willingness to make the time commitment to participate in the project, including randomization to treatments * physically inactive (physical activity not more than 2 days per week for the past 6 months) * physician consent to undergo an exercise stress test and engage in moderate intensity exercise * determined to be safe for mri exclusion criteria: * neurological illnesses/conditions such as cerebral palsy, epi¬lepsy, brain tumor, chronic meningitis, multiple scle¬rosis, pernicious anemia, normal-pressure hydrocephalus, hiv infection, parkinson's disease, and huntington's disease * untreated hypertension, glaucoma, and chronic obstructive pul¬monary disease * untreated severe major depression * substance abuse or dependence * current use of psychoactive medications, except selective serotonin/norepinephrine reuptake inhibitor antidepressants * use of acetylcholinesterase inhibitors (e.g., aricept) * unstable or severe cardiovascular disease or asthmatic condition * history of transient ischemic attack, cerebral ischemia, or clinically diagnosed stroke * diagnosis of mild cognitive impairment or dementia, or objective evidence of cognitive impairment

Keywords: walking exercise flexibility exercise cognition memory magnetic resonance imaging